• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Summary: Bausch & Lomb Inc. May 11 Product Image

Summary: Bausch & Lomb Inc. May 11

  • ID: 1806856
  • May 2011
  • Standard & Poors

The speculative-grade rating on Rochester, N.Y.-based Bausch & Lomb Inc. reflects Standard & poor's Ratings Services' expectations that EBITDA and cash flow will continue to improve, largely as a result of restructuring efforts; in addition to reducing run-rate operating expenses, one time restructuring costs have largely been expended. Notwithstanding the resulting improvement in financial metrics, we expect the company's financial risk profile to remain highly leveraged in the near term; debt leverage has been high since the company's acquisition by Warburg Pincus in October 2007. The company's fair business risk profile reflects its lackluster performance over the past few years, although strong growth in pharmaceutical sales has offset declines in the vision care and surgical business segments. Total revenue growth...

Companies mentioned in this report are: Bausch & Lomb Inc.
Action: Review

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine READ MORE >

Note: Product cover images may vary from those shown

Bausch & Lomb Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Fluidigm Corporation Apple, Inc. CEVA Santé Animale Abbott Laboratories Ltd. Merck Group Allergan Inc. Pfizer, Inc.